Alliance Pharma PLC Total Voting Rights (8426X)

TIDMAPH

RNS Number : 8426X

Alliance Pharma PLC

02 September 2020

 
 For immediate release   2 September 2020 
 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 28 August 2020 the Company's issued share capital consists of 531,236,180 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 531,236,180 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Alliance Pharma plc + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk

Buchanan + 44 (0) 20 7466 5000

Mark Court / Hannah Ratcliff

Numis Securities Limited

+ 44 (0) 20 7260 1000

Nominated Adviser: Freddie Barnfield / Huw Jeremy

Corporate Broking: James Black

Investec Bank plc [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Tejas Padalkar

About Alliance Pharma

Alliance Pharma plc (AIM: APH) is an international healthcare group, headquartered in the UK with subsidiaries in Europe, the Far East and the US and wide international reach through an extensive network of distributors, generating revenues in more than 100 countries.

We currently own or license the rights to around 90 consumer healthcare products and pharmaceuticals, which are managed on a portfolio basis according to their growth potential. Promotional investment is focused on a small number of brands with significant international or multi-territory reach. The remainder of the portfolio comprises products which are sold in a limited number of local markets and require little or no promotional investment.

Our strategy allows us to deliver good organic growth and to enhance our growth rate through carefully selected acquisitions.

For more information on Alliance, please visit our website : www.alliancepharmaceuticals.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRUPUCWBUPUGGP

(END) Dow Jones Newswires

September 02, 2020 07:37 ET (11:37 GMT)